Introduction
During vaccination, vaccine antigens would be captured and processed by a specific immune cell type, known as dendritic cells, for the induction of antigen-specific immune responses. Unfortunately, this antigen processing pathway is usually not efficient.
Our patented PD-1-enhanced DNA vaccine technology platform targets the PD-1 ligands, including PD-L1, on the dendritic cells for effective antigen delivery, which could efficiently induce potent protective immune responses for active suppression of viruses and tumour cells to allow substantial improvement of prevention and treatment outcomes.
Key characteristics of PD-1-Enhanced DNA vaccine
PD-1-enhanced DNA vaccine platform can be efficiently applied to generate highly efficacious DNA vaccines for various infectious diseases and cancers which have clear advantages over traditional vaccine in terms of development time, stability, safety, cost, and more importantly, effectiveness.
PD-1-Enhanced DNA vaccine platform explained
A PD‑1-Enhanced DNA vaccine is generated by cloning an optimised DNA sequence encoding PD‑1‑linked antigen to our DNA plasmid backbone. The vaccine is then administered intramuscularly with electroporation. Electroporation enhances the delivery of the DNA vaccine into muscle cells. The muscle cells will act as mini-factories to produce PD-1-linked antigens. The PD‑1 domain of the antigen will allow effective antigen targeting to dendritic cells, an essential cell type for inducing potent T cell and B cell responses. This process builds up protective memory immunity in the body to fight off virus infections and cancers.